Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jul 1;1(1):154-165.
doi: 10.1089/can.2016.0009. eCollection 2016.

Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes

Affiliations
Free PMC article
Review

Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes

Ethan B Russo. Cannabis Cannabinoid Res. .
Free PMC article

Abstract

Medicine continues to struggle in its approaches to numerous common subjective pain syndromes that lack objective signs and remain treatment resistant. Foremost among these are migraine, fibromyalgia, and irritable bowel syndrome, disorders that may overlap in their affected populations and whose sufferers have all endured the stigma of a psychosomatic label, as well as the failure of endless pharmacotherapeutic interventions with substandard benefit. The commonality in symptomatology in these conditions displaying hyperalgesia and central sensitization with possible common underlying pathophysiology suggests that a clinical endocannabinoid deficiency might characterize their origin. Its base hypothesis is that all humans have an underlying endocannabinoid tone that is a reflection of levels of the endocannabinoids, anandamide (arachidonylethanolamide), and 2-arachidonoylglycerol, their production, metabolism, and the relative abundance and state of cannabinoid receptors. Its theory is that in certain conditions, whether congenital or acquired, endocannabinoid tone becomes deficient and productive of pathophysiological syndromes. When first proposed in 2001 and subsequently, this theory was based on genetic overlap and comorbidity, patterns of symptomatology that could be mediated by the endocannabinoid system (ECS), and the fact that exogenous cannabinoid treatment frequently provided symptomatic benefit. However, objective proof and formal clinical trial data were lacking. Currently, however, statistically significant differences in cerebrospinal fluid anandamide levels have been documented in migraineurs, and advanced imaging studies have demonstrated ECS hypofunction in post-traumatic stress disorder. Additional studies have provided a firmer foundation for the theory, while clinical data have also produced evidence for decreased pain, improved sleep, and other benefits to cannabinoid treatment and adjunctive lifestyle approaches affecting the ECS.

Keywords: Huntington disease; Parkinson disease; THC; anandamide; anorexia nervosa; cannabidiol; cannabinoids; depression; endocannabinoids; fibromyalgia; irritable bowel syndrome; migraine; motion sickness; multiple sclerosis; post-traumatic stress disorder; prebiotics.

Conflict of interest statement

No competing financial interests exist.

Figures

<b>FIG. 1.</b>
FIG. 1.
Diagram depicting comorbidity of migraine, fibromyalgia, and irritable bowel syndrome.
<b>FIG. 2.</b>
FIG. 2.
Anandamide levels in cerebrospinal fluid of chronic migraine patients versus controls, adapted from data obtained from Sarchielli et al.
<b>FIG. 3.</b>
FIG. 3.
Bar graph of change in migraine frequency after cannabis treatment, adapted from data from Rhyne et al.
<b>FIG. 4.</b>
FIG. 4.
Bar graph depicting decreases in pain in the per-protocol subset of fibromyalgia patients taking THC, adapted from data from Schley et al. THC, tetrahydrocannabinol (dronabinol).
<b>FIG. 5.</b>
FIG. 5.
Efficacy of approved pharmaceuticals compared with cannabis in fibromyalgia according to patient survey results, adapted from data from National Pain Report.

Similar articles

See all similar articles

Cited by 14 articles

See all "Cited by" articles

References

    1. Russo EB. Hemp for headache: an in-depth historical and scientific review of cannabis in migraine treatment. J Cannabis Ther. 2001;1:21–92
    1. Russo EB. Handbook of psychotropic herbs: a scientific analysis of herbal remedies for psychiatric conditions. Haworth Press: Binghamton, NY, 2001
    1. Russo EB. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuroendocrinol Lett. 2004;25:31–39 - PubMed
    1. McPartland JM, Guy GW, Di Marzo V. Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system. PLoS One. 2014;9:e89566. - PMC - PubMed
    1. Pacher P, Kunos G. Modulating the endocannabinoid system in human health and disease—successes and failures. FEBS J. 2013;280:1918–1943 - PMC - PubMed

LinkOut - more resources

Feedback